NCT00944827

Brief Summary

There is a positive correlation between serum's cholesterol levels and death from cardiovascular disease, especially coronary artery disease. The reduction of plasma lipids levels is one of the main goals of prevention. Research has shown that green tea has beneficial effects on health due to the polyphenolic substances (catechins) that it contains. Studies have shown that prolonged consumption of polyphenols has a positive effect on factors related to cardiovascular risk such as obesity, dislipidemia and various indicators of oxidative stress. The aim of this study was to examine the possible effects of catechin supplementation, in combination with the classic treatment for the reduction of hypercholesterolemia, statin therapy, on the treatment's effectiveness and in the reduction of classic side effects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Sep 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

July 21, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 23, 2009

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2009

Completed
Last Updated

December 3, 2010

Status Verified

July 1, 2009

Enrollment Period

2.1 years

First QC Date

July 21, 2009

Last Update Submit

December 2, 2010

Conditions

Keywords

Green Tea ExtractCatechinsStatinatorvastatinbody compositionvisceral fatsteatosisoxidative stressquality of lifeOGTTOGISISI matsuda

Outcome Measures

Primary Outcomes (1)

  • Reduction in Total CHO and LDH

    12 wks

Secondary Outcomes (1)

  • lipids profile, body composition, visceral adiposity, Redox status, glucose disposal, Insulin sensitivity index, liver fat infiltration, quality of life parameters

    12 wks

Study Arms (2)

GTE

EXPERIMENTAL

The experimental group will receive 20 mg atorvastatin (Lipitor) daily and 600 mg. of pure catechin in capsules

Dietary Supplement: Green Tea Extract - Catechins

CON

PLACEBO COMPARATOR

The control group will receive 20 mg atorvastatin (Lipitor) and Placebo in identical capsules containing 600 mg placebo for 12 weeks

Dietary Supplement: Placebo

Interventions

Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks

GTE
PlaceboDIETARY_SUPPLEMENT

Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks

CON

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Total cholesterol \>200mg/dl, or LDL \>160 mg/dl

You may not qualify if:

  • normal lipidemic profile, on statin medication, diabetes mellitus, liver disease, severe hypertension, pregnancy, or severe side effects after 4 weeks of treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

General Hospital of Trikala

Trikala, Thessaly, 42100, Greece

Location

MeSH Terms

Conditions

HypercholesterolemiaFatty Liver

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesLiver DiseasesDigestive System Diseases

Study Officials

  • Giorgos K Sakkas, PhD

    UTH - CERETETH

    PRINCIPAL INVESTIGATOR
  • Christina Karatzaferi, PhD

    University of Thessaly

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 21, 2009

First Posted

July 23, 2009

Study Start

September 1, 2007

Primary Completion

October 1, 2009

Study Completion

October 1, 2009

Last Updated

December 3, 2010

Record last verified: 2009-07

Locations